Effect of IL-18 on the percent of splenic cellular phenotype
Group . | Total cells . | %CD4+ . | %CD8+ . | % B220+ . | %Gr-1+ . |
---|---|---|---|---|---|
Diluent | 110.4 ± 7.8 × 106 | 24% ± 5% | 13% ± 3% | 51% ± 9% | 2.5% ± 0.6% |
IL-18 | 179.8 ± 12 × 106* | 19% ± 6% | 9% ± 3.8% | 46% ± 14% | 13.4% ± 1.27%* |
Group . | Total cells . | %CD4+ . | %CD8+ . | % B220+ . | %Gr-1+ . |
---|---|---|---|---|---|
Diluent | 110.4 ± 7.8 × 106 | 24% ± 5% | 13% ± 3% | 51% ± 9% | 2.5% ± 0.6% |
IL-18 | 179.8 ± 12 × 106* | 19% ± 6% | 9% ± 3.8% | 46% ± 14% | 13.4% ± 1.27%* |
BALB/c mice (n = 3/group) were injected with 1 μg/day of IL-18 or the diluent (control) for 10 days. Splenocytes were harvested on day 11 and analyzed for cellular phenotype by 2-colored flow cytometry. IL-18 treatment increased the total number of cells and the percent of Gr-1 cells (
P < .03) but did not significantly alter the ratios of CD4+, CD8+, or B220+ cells.